Purple Biotech Ltd - ADR
PPBT
Get informed when a big investor buys or sells
+ FollowMarket Cap$412.87K
Close$
$0.21
92.9% downside
Current Fair Value
92.9% downsideOvervalued by 92.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $412,871.00 |
|---|---|
| Enterprise Value | $-4,970,129.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11080 |
| Beta | -0.57 |
| Outstanding Shares | 4,647 |
Return
| Return on Equity | -271.21% |
|---|---|
| Return on Assets | -182.89% |
| Return on Invested Capital | -265.12% |
Valuation & Multiples
| P/E Ratio | -0.25 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.19 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 27, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 380.00% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3151.99%▼ 100.01% |
|---|---|
| Total Invested | $305,645▼ 40.45% |
| Investors Holding | 14▼ 6.00% |
ESG Score
No data
About Purple Biotech Ltd
CEO: Itzhak Israel